- CRDF Dashboard
- Financials
- Filings
-
Holdings
- Transcripts
- ETFs
- Insider
- Institutional
- Shorts
-
CORRESP Filing
Cardiff Oncology (CRDF) CORRESPCorrespondence with SEC
Filed: 6 Sep 19, 12:00am
Trovagene, Inc.
11055 Flintkote Avenue
San Diego, CA 92121
|
| September 6, 2019 |
VIA EDGAR
United States Securities and Exchange Commission
100 F Street, N.E.
Washington, D.C. 20549
Attention: Sonia Bednarowski
Re: Trovagene, Inc.
Form S-1
File No. 333-233568
Ladies and Gentlemen:
Pursuant to Rule 461 of the General Rules and Regulations under the Securities Act of 1933, as amended (the “Act”), Trovagene, Inc. (the “Company”) respectfully requests that the effective date of the registration statement referred to above be accelerated so that it will become effective at 4:30 p.m., Eastern Daylight Time, on Tuesday, September 10, 2019, or as soon thereafter as possible.
Please notify Jeffrey Fessler of Sheppard, Mullin, Richter & Hampton LLP, counsel to the Company, at (212) 634-3067 as soon as possible as to the time the Registration Statement has been declared effective pursuant to this acceleration request.
|
| Thank you, | |
|
|
| |
|
| TROVAGENE, INC. | |
|
|
| |
|
|
| |
|
| By: | /s/ Thomas Adams |
|
| Name: | Thomas Adams |
|
| Title: | Chief Executive Officer |